| ‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA |
| A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19 |
| A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |
| A Potential Role of the Spike Protein in Neurodegenerative Diseases: A Narrative Review |
| A Report on the U.S. Vaccine Adverse Events Reporting System (VAERS) of the COVID-19 Messenger Ribonucleic Acid (mRNA) Biologicals |
| Adverse effects of COVID-19 vaccines and measures to prevent them |
| Affidavit of LTC. Theresa Long M.D. in Support of a Motion for a Preliminary Injunction Order |
| Alternate mechanisms of mRNA vaccine toxicity: which one is the main culprit? |
| An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies |
| Anaphylaxis-Induced Acute Coronary Syndrome Following Covid-19 mRNA-LNP Vaccination: Mechanisms and Therapeutic Approaches |
| CDC REMOVES Their Claim That mRNA & Spike Protein "Do Not Last Long In The Body” |
| Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis |
| Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis |
| Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants |
| Concerns regarding Transfusions of Blood Products Derived from Genetic Vaccine Recipients and Proposals for Specific Measures |
| COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 1 |
| COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 2 |
| COVID-19 Vaccine: Critical Questions with Complicated Answers |
| COVID-19 vaccines – An Australian Review |
| Critical appraisal of multidrug therapy in the ambulatory management of patients with COVID-19 and hypoxemia |
| Delayed Induction of Noninflammatory SARS-CoV-2 Spike-Specific IgG4 Antibodies Detected 1 Year After BNT162b2 Vaccination in Children |
| Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms |
| Differences in Vaccine and SARS-CoV-2 Replication Derived mRNA: Implications for Cell Biology and Future Disease |
| DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events. |
| Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019 |
| Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 |
| Endonuclease fingerprint indicates a synthetic origin of SARS-CoV-2 |
| Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients |
| Excess Deaths in the United Kingdom: Midazolam and Euthanasia in the COVID-19 Pandemic |
| Expert testimony of Dr. Christina Parks, PhD |
| Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice |
| Fauci on Antibody Dependent Enhancement (ADE) |
| Fibrin drives thromboinflammation and neuropathology in COVID-19 |
| Funeral Director Tells All |
| Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis |
| Homology between SARS CoV-2 and human proteins |
| How COVID Shots Suppress Your Immune System |
| Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination |
| Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus |
| Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease |
| Innate Immune Suppression by SARS-CoV-2 mRNA Vaccinations: The role of G-quadruplexes, exosomes and microRNAs |
| Interview with Dr. Robert Malone, inventor of some important mRNA-vaccine technology |
| Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line |
| Letter to U.S. Food and Drug Administration, Vaccines and Related Biological Products Advisory Committee in response to “Request for Comments related to consideration of vaccines against SARS-CoV-2” |
| Maternal COVID-19 Vaccination and Its Potential Impact on Fetal and Neonatal Development |
| Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America |
| Medical Countermeasures Analysis of 2019-nCoV and Vaccine Risks for Antibody-Dependent Enhancement (ADE) |
| Moderna clinical trial: A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 |
| mRNA Platform: Enabling Drug Discovery & Development |
| mRNA Vaccine Toxicity |
